Orphan Drugs 19th – 20th October 2015 Holiday Inn Regents Park, London

Several thousand different types of rare diseases and disorders exist, with more being discovered each day. As a result, in recent years, the interest for rare diseases has grown throughout the entire medical community. However, the road to an approved orphan drug is a long, challenging and costly one with many challenges on the way including regulatory, financial, sustainability and pricing and reimbursement issues.

Returning for its fourth year and following on from the major success of previous events, SMi are proud to present the 4th annual Orphan Drugs and Rare Diseases Conference, 19th – 20th October 2015, London, UK. Through a series of interactive presentations and panel discussions, join us and learn how payers, pharmaceutical, biotech, patient organisations and academia are structuring to participate in and leverage the growing orphan market.

Key topics include:

• Development of ultra-orphan drugs to prevent, diagnose and treat rare diseases
• Financing orphan diseases: a risk/benefit evaluation of investing in orphan drugs
• The regulatory landscape of orphan drugs - what you need to know and why
• How to establish a wokable foundation for reimbursement
• Partnering and establishing partnerships for future development